Literature DB >> 17065630

Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae.

Glenn A Pankuch1, Dianne Hoellman, André Bryskier, John Lowther, Peter C Appelbaum.   

Abstract

The activity of NXL103 against 108 strains of Haemophilus influenzae was tested using Haemophilus test media (HTM) obtained from various sources. With the exception of those obtained with stored HTM, MICs did not differ significantly, with MIC(50) and MIC(90) values of 0.5 and 0.5 to 1 microg/ml, respectively, in each medium.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17065630      PMCID： PMC1635171          DOI： 10.1128/AAC.00587-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.

Authors:  M R Jacobs
Journal:  Clin Microbiol Infect       Date:  2001-11       Impact factor: 8.067

2.  Contribution of beta-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in beta-lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae.

Authors:  Vlatka Matic; Bülent Bozdogan; Michael R Jacobs; Kimiko Ubukata; Peter C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790

3.  Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez; Andre Bryskier
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.

Authors:  M L Zeckel; K D Jacobson; F J Guerra; D G Therasse; D Farlow
Journal:  Clin Ther       Date:  1992 Mar-Apr       Impact factor: 3.393

5.  Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media.

Authors:  R Dagan; C E Johnson; S McLinn; N Abughali; J Feris; E Leibovitz; D J Burch; M R Jacobs
Journal:  Pediatr Infect Dis J       Date:  2000-02       Impact factor: 2.129

6.  Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children.

Authors:  R Dagan; E Leibovitz; D M Fliss; A Leiberman; M R Jacobs; W Craig; P Yagupsky
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

7.  Susceptibility of European beta-lactamase-positive and -negative Haemophilus influenzae isolates from the periods 1997/1998 and 2002/2003.

Authors:  A C Fluit; A Florijn; J Verhoef; D Milatovic
Journal:  J Antimicrob Chemother       Date:  2005-05-25       Impact factor: 5.790

8.  Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates.

Authors:  Mihaela Peric; Bülent Bozdogan; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

9.  Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in Haemophilus influenzae HMC-S.

Authors:  Mihaela Peric; Bülent Bozdogan; Chad Galderisi; Dan Krissinger; Terry Rager; Peter C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2004-07-08       Impact factor: 5.790

10.  Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.

Authors:  Glenn A Pankuch; Linda M Kelly; Gengrong Lin; Andre Bryskier; Catherine Couturier; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191
View more
  1 in total

Review 1.  NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA.

Authors:  Amani D Politano; Robert G Sawyer
Journal:  Curr Opin Investig Drugs       Date:  2010-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.